Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

1 2356 8 4 7 9n109 10 The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Atkins, Robert Charles, Chadban, Steven James, Cooper, Mark Emmanuel, Gilbert, Richard Ernest, Hill, Prudence Ann, Kelly, Darren James, Nikolic-Paterson, David John
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Atkins, Robert Charles
Chadban, Steven James
Cooper, Mark Emmanuel
Gilbert, Richard Ernest
Hill, Prudence Ann
Kelly, Darren James
Nikolic-Paterson, David John
description 1 2356 8 4 7 9n109 10 The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein Ris pyridyl bonded at a carbon atom, R, R, R, Rand Rare each hydrogen, Ris lower alkyl, Ra radical of formula (II): -N(R)-C(═X)-(Y)-R, wherein Rhydrogen, X is oxo, n is 0 and Ris 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.
format Patent
fullrecord <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_07087608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>07087608</sourcerecordid><originalsourceid>FETCH-uspatents_grants_070876083</originalsourceid><addsrcrecordid>eNqNizEOwjAMALMwIOAP_gBSJCTaHVoYGWBgQm5xiAUkUWyG_p5E4gFMN9zd3FwvQhAdnPaHHjKNlDRm0ClH4UDw5IAl4OB54GIEXNWeQDOhvilove-MAymPECj5HBOqn5Zm5vAltPpxYaDvzrvj-iPFl1Fuj4wVtrFts7Xt5o_kC2x4O4g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy</title><source>USPTO Issued Patents</source><creator>Atkins, Robert Charles ; Chadban, Steven James ; Cooper, Mark Emmanuel ; Gilbert, Richard Ernest ; Hill, Prudence Ann ; Kelly, Darren James ; Nikolic-Paterson, David John</creator><creatorcontrib>Atkins, Robert Charles ; Chadban, Steven James ; Cooper, Mark Emmanuel ; Gilbert, Richard Ernest ; Hill, Prudence Ann ; Kelly, Darren James ; Nikolic-Paterson, David John</creatorcontrib><description>1 2356 8 4 7 9n109 10 The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein Ris pyridyl bonded at a carbon atom, R, R, R, Rand Rare each hydrogen, Ris lower alkyl, Ra radical of formula (II): -N(R)-C(═X)-(Y)-R, wherein Rhydrogen, X is oxo, n is 0 and Ris 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.</description><language>eng</language><creationdate>2006</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7087608$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,780,802,885,64039</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7087608$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Atkins, Robert Charles</creatorcontrib><creatorcontrib>Chadban, Steven James</creatorcontrib><creatorcontrib>Cooper, Mark Emmanuel</creatorcontrib><creatorcontrib>Gilbert, Richard Ernest</creatorcontrib><creatorcontrib>Hill, Prudence Ann</creatorcontrib><creatorcontrib>Kelly, Darren James</creatorcontrib><creatorcontrib>Nikolic-Paterson, David John</creatorcontrib><title>Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy</title><description>1 2356 8 4 7 9n109 10 The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein Ris pyridyl bonded at a carbon atom, R, R, R, Rand Rare each hydrogen, Ris lower alkyl, Ra radical of formula (II): -N(R)-C(═X)-(Y)-R, wherein Rhydrogen, X is oxo, n is 0 and Ris 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2006</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNqNizEOwjAMALMwIOAP_gBSJCTaHVoYGWBgQm5xiAUkUWyG_p5E4gFMN9zd3FwvQhAdnPaHHjKNlDRm0ClH4UDw5IAl4OB54GIEXNWeQDOhvilove-MAymPECj5HBOqn5Zm5vAltPpxYaDvzrvj-iPFl1Fuj4wVtrFts7Xt5o_kC2x4O4g</recordid><startdate>20060808</startdate><enddate>20060808</enddate><creator>Atkins, Robert Charles</creator><creator>Chadban, Steven James</creator><creator>Cooper, Mark Emmanuel</creator><creator>Gilbert, Richard Ernest</creator><creator>Hill, Prudence Ann</creator><creator>Kelly, Darren James</creator><creator>Nikolic-Paterson, David John</creator><scope>EFH</scope></search><sort><creationdate>20060808</creationdate><title>Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy</title><author>Atkins, Robert Charles ; Chadban, Steven James ; Cooper, Mark Emmanuel ; Gilbert, Richard Ernest ; Hill, Prudence Ann ; Kelly, Darren James ; Nikolic-Paterson, David John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_070876083</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2006</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Atkins, Robert Charles</creatorcontrib><creatorcontrib>Chadban, Steven James</creatorcontrib><creatorcontrib>Cooper, Mark Emmanuel</creatorcontrib><creatorcontrib>Gilbert, Richard Ernest</creatorcontrib><creatorcontrib>Hill, Prudence Ann</creatorcontrib><creatorcontrib>Kelly, Darren James</creatorcontrib><creatorcontrib>Nikolic-Paterson, David John</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Atkins, Robert Charles</au><au>Chadban, Steven James</au><au>Cooper, Mark Emmanuel</au><au>Gilbert, Richard Ernest</au><au>Hill, Prudence Ann</au><au>Kelly, Darren James</au><au>Nikolic-Paterson, David John</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy</title><date>2006-08-08</date><risdate>2006</risdate><abstract>1 2356 8 4 7 9n109 10 The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein Ris pyridyl bonded at a carbon atom, R, R, R, Rand Rare each hydrogen, Ris lower alkyl, Ra radical of formula (II): -N(R)-C(═X)-(Y)-R, wherein Rhydrogen, X is oxo, n is 0 and Ris 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_uspatents_grants_07087608
source USPTO Issued Patents
title Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A10%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Atkins,%20Robert%20Charles&rft.date=2006-08-08&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E07087608%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true